A PHASE II TRIAL OF GEMCITABINE, IFOSFAMIDE, DEXAMATHASONE, AND OXALIPLATIN (GIDOX) FOR PATIENTS WITH REFRACTORY OR RELAPSED NON-HODGKIN'S LYMPHOMA

被引：0
|
作者：
Park, B. B. [1 ]
Kim, W. S. [2 ]
Eom, H. S. [3 ]
Kim, J. S. [4 ]
Oh, S. J. [5 ]
Hwang, I. G. [6 ]
Suh, C. [7 ]
机构：
[1] Hanyang Univ, Coll Med, Seoul 133791, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea
[4] Yonsei Univ, Coll Med, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Seoul, South Korea
[6] Chung Ang Univ, Sch Med, Seoul 156756, South Korea
[7] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1701
引用
收藏
页码：652 / 652
页数：1
相关论文
共 50 条
  • [31] Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    Kallam, Avyakta
    Meza, Jane
    Bierman, Philip
    Lunning, Matthew A.
    Bociek, R. Gregory
    Armitage, James Olen
    Vose, Julie M.
    BLOOD, 2017, 130
  • [32] Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial
    Jo, Jae-Cheol
    Baek, Jin Ho
    Lee, Je-Hwan
    Joo, Young-Don
    Bae, Sung-Hwa
    Lee, Jung-Lim
    Lee, Jung-Hee
    Kim, Dae-Young
    Lee, Won-Sik
    Ryoo, Hun Mo
    Choi, Yunsuk
    Kim, Hawk
    Lee, Kyoo-Hyung
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 (02) : 159 - 166
  • [33] Two consecutive phase II studies of oxaliplatin based salvage chemotherapy for treatment of patients with refractory or relapsed non-Hodgkin's lymphoma.
    Delmas-Marsalet, B
    Gumus, Y
    Misra, S
    Goldschmidt, E
    Frenoy, N
    Guettier, C
    Brahimi, N
    Ulusakarya, A
    Jasmin, C
    Machover, D
    BLOOD, 2002, 100 (11) : 297B - 297B
  • [34] Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
    Fosså, A
    Santoro, A
    Hiddemann, W
    Truemper, L
    Niederle, N
    Buksmaui, S
    Bonadonna, G
    Seeber, S
    Nowrousian, MR
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) : 3786 - 3792
  • [35] Gemcitabine combined with oxaliplatin in the treatment of relapsed or refractory Hodgkin lymphoma
    Coliat, P.
    El Aatmani, A.
    Berceanu, A.
    Leveque, D.
    Herbrecht, R.
    Beretz, L.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 459 - 459
  • [36] Phase I Trial of Bortezomib and Everolimus in Relapsed/Refractory Non-Hodgkin Lymphoma
    Hill, Brian T.
    Smith, Mitchell R.
    Mears, Jennifer
    Healy, Amy
    Shelley, Meredeth
    Wyckhouse, Jeanie
    Kakish, Janice
    Jagadeesh, Deepa
    Dean, Robert M.
    Pohlman, Brad
    Smith, Stephen D.
    BLOOD, 2014, 124 (21)
  • [37] Gemcitabine in Combination with Oxaliplatin (GEMOX) As a Salvage Regimen in Patients with Relapsed/Refractory Hodgkin's Lymphoma
    Ozdemir, Evren
    Aslan, Alma
    Turker, Alev
    Barista, Ibrahim
    Kars, Ayse
    BLOOD, 2015, 126 (23)
  • [38] A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
    Younes, A.
    Vose, J. M.
    Zelenetz, A. D.
    Smith, M. R.
    Burris, H. A.
    Ansell, S. M.
    Klein, J.
    Halpern, W.
    Miceli, R.
    Kumm, E.
    Fox, N. L.
    Czuczman, M. S.
    BRITISH JOURNAL OF CANCER, 2010, 103 (12) : 1783 - 1787
  • [39] Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Kuruvilla, John
    Taylor, Diane
    Wang, Lisa
    Blattler, Chantale
    Keating, Armand
    Crump, Michael
    BLOOD, 2008, 112 (11) : 1049 - 1049
  • [40] Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    William, Basem M.
    Hohenstein, Maribeth
    Loberiza, Fausto R., Jr.
    Caponetti, Gabriel C.
    Bociek, R. Gregory
    Bierman, Philip
    Armitage, James O.
    Chan, Wing-Chung
    Vose, Julie M.
    BLOOD, 2010, 116 (21) : 131 - 131
12345